Loading…
Bioreduction of methyl o-chlorobenzoylformate at 500ANBgANBLa1 without external cofactors for efficient production of enantiopure clopidogrel intermediate
Biocatalytic reduction of methyl o-chlorobenzoylformate (CBFM) provides a green and direct access to methyl (R)-o-chloromandelate [(R)-CMM], an intermediate for a platelet aggregation inhibitor named clopidogrel. As much as 500 g La1 of CBFM was stoichiometrically converted into enantiopure (R)-CMM...
Saved in:
Published in: | Tetrahedron letters 2012-08, Vol.53 (35), p.4715-4717 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Biocatalytic reduction of methyl o-chlorobenzoylformate (CBFM) provides a green and direct access to methyl (R)-o-chloromandelate [(R)-CMM], an intermediate for a platelet aggregation inhibitor named clopidogrel. As much as 500 g La1 of CBFM was stoichiometrically converted into enantiopure (R)-CMM at 20 degree C by using a whole-cell catalyst coexpressing an aldo-keto reductase from Bacillus sp. and a glucose dehydrogenase (GDH). In addition to the high productivity of 812 g La1 da1, this new whole-cell reduction is attractive by eliminating the need of an added external cofactor. |
---|---|
ISSN: | 0040-4039 |
DOI: | 10.1016/j.tetlet.2012.06.097 |